Histogenics Acquires Rights to NeoCart for the Japanese Market
Histogenics acquired development and commercialization rights to NeoCart® for the Japanese market from its partner, Purpose Co. NeoCart autologous cell therapy is designed to treat knee cartilage defects. May 10, 2016